{"id":613868,"date":"2026-09-16T23:30:43","date_gmt":"2026-09-16T23:30:43","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/613868\/creative-biolabs-expands-in-vitro-adme-support-for-early-drug-discovery.html"},"modified":"2026-09-16T23:30:43","modified_gmt":"2026-09-16T23:30:43","slug":"creative-biolabs-expands-in-vitro-adme-support-for-early-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/613868\/creative-biolabs-expands-in-vitro-adme-support-for-early-drug-discovery.html","title":{"rendered":"Creative Biolabs Expands In Vitro ADME Support for Early Drug Discovery"},"content":{"rendered":"
Creative Biolabs has expanded its in vitro ADME resources and service workflow to help drug discovery teams.<\/div>\n

New York, USA – September 16, 2026 –<\/strong> The Importance of Early ADME Profiling Early in vitro ADME (Absorption, Distribution, Metabolism, and Excretion) studies<\/a> help researchers identify compounds with unfavorable absorption, distribution, metabolism, or interaction profiles before committing resources to more complex in vivo<\/em> studies. Creative Biolabs’ expanded workflow brings together complementary assays and scientific interpretation to support stage-appropriate decisions from hit-to-lead selection through preclinical development.<\/p>\n

\"\"<\/p>\n

Poor pharmacokinetic properties remain an important contributor to candidate attrition. Evaluating these properties early helps identify exposure, metabolism, drug-drug interaction (DDI), and selected safety-related risks. Aligning with regulatory frameworks—such as the FDA’s guidance on in vitro<\/em> drug interaction studies—provides a solid scientific basis for identifying potential interaction mechanisms and directly informs the design of subsequent clinical DDI studies.<\/p>\n

Comprehensive<\/strong> In Vitro<\/em> Assays and Decision-Making<\/strong><\/p>\n

To support targeted early-stage decision-making, the expanded service portfolio addresses specific developmental milestones:<\/p>\n

Solubility and Permeability:<\/strong> Utilizing Caco-2 and PAMPA models to predict intestinal absorption, aiding in the selection of viable oral candidates and informing formulation strategies.<\/p>\n

Protein Binding:<\/strong> Assessing plasma protein binding across various species to determine the unbound, pharmacologically active fraction of a therapeutic candidate, a critical metric for predicting efficacy.<\/p>\n

Metabolic Stability:<\/strong> Leveraging human and animal liver microsomes, as well as primary hepatocytes, to evaluate intrinsic clearance, predict in vivo<\/em> half-life, and flag vulnerable metabolic liabilities early.<\/p>\n

Enzyme and Transporter Assays:<\/strong> Screening for CYP450 and UGT enzyme inhibition or induction, alongside key transporter assays (e.g., P-gp, BCRP), to anticipate how a compound might interact with co-administered medications.<\/p>\n

An Integrated Workflow for R&D Value<\/strong><\/p>\n

Transitioning from macro-level strategy to bench-level execution requires rigorous scientific methodology. Creative Biolabs’ reorganized workflow bridges physicochemical property evaluation with absorption, distribution, metabolism, DDI risks, and necessary in vivo<\/em> PK considerations.<\/p>\n

While in vitro<\/em> models do not completely replace the need for in vivo<\/em> animal or clinical studies, applying these standardized protocols can improve consistency and support reproducible decision-making when appropriately qualified. This proactive screening approach allows for the rapid identification and elimination of candidates with sub-optimal profiles, potentially reducing downstream cost and resource use. With flexible testing models spanning multiple species (including human, rodent, canine, and non-human primate) and diverse analytical platforms like LC-MS\/MS, the workflow is designed to accommodate a wide variety of molecular types.<\/p>\n

Expert Perspective<\/strong><\/p>\n

“The value of early ADME screening<\/a> is not simply generating more data but selecting assays that answer the right development question at each stage,” said a senior scientific director at Creative Biolabs. “Our updated framework ensures that our partners have the exact technical protocols and context needed to make informed, stage-appropriate decisions.”<\/p>\n

As global drug discovery networks continue to prioritize comprehensive, authoritative scientific content, Creative Biolabs’ structured ADME resources stand as a practical starting point for pharmaceutical innovators.<\/p>\n

To explore Creative Biolabs’ full suite of focused ADME and preclinical drug discovery solutions, please visit https:\/\/www.creative-biolabs.com\/drug-discovery\/therapeutics<\/a>.<\/p>\n

About Creative Biolabs<\/strong><\/p>\n

Creative Biolabs is a global biotechnology company providing a comprehensive range of custom services in antibody development, drug discovery, and preclinical screening. With a commitment to scientific excellence, the company supports researchers worldwide in navigating the complexities of therapeutic development, offering customized solutions for ADME\/DMPK profiling, pharmacology, and toxicology.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs
Contact Person:<\/strong> Candy Swift
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-830-6441
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/drug-discovery\/therapeutics<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Creative Biolabs has expanded its in vitro ADME resources and service workflow to help drug discovery teams. New York, USA – September 16, 2026 – The Importance of Early ADME<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/613868"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=613868"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/613868\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=613868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=613868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=613868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}